Skip to main content

Advertisement

SpringerLink
Log in

Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

The aims of this study were to evaluate the persistence, the adherence on treatment with mirabegron, the reasons for the interruption in patients with overactive bladder syndrome (OAB) and their satisfaction.

Methods

This was an Italian multicentre prospective study. Four tertiary urological centers were involved. We included women with no neurogenic OAB symptoms already in therapy with once-daily mirabegron 50 mg for 1 month. They were followed up at 1, 3 and 6 months post-treatment with uroflowmetry with voiding diary for 3 days and post-void residual measurement. They completed self-administered Overactive Bladder questionnaire short form (OABq), Morisky Medication Adherence Scale-4 short form (MMAS), Patient Global Impression-Improvement questionnaire. Patients were divided in OAB wet and OAB dry groups, and in treatment-naive and treatment-experienced groups.

Results

Between January 2018 and July 2018, 80 patients with OAB were included. Fifteen (18.7%) patients continued the treatment for 6 months; 17.5% interrupted the therapy before 1 month: 30% within the third month, while, 33.7% after 1 month. The median time to discontinuation with mirabegron was 62.5 days. The mean adherence was 0.42 ± 0.33, median MMAS was 2 (0–4). The adherence was significantly greater in treatment-naïve (22.4%) than treatment-experienced (6.5%) patients, without statistically significant differences in the different OAB form. The cost is the main cause of interruption of therapy (50% of cases).There was an improvement of OABqSF score and PGI-I score.

Conclusion

In Italy, the cost compromises adherence and persistence of therapy with mirabegron despite the good functional outcomes

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P (2009) Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 28:287

    Article  Google Scholar 

  2. Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59:931–937

    Article  CAS  Google Scholar 

  3. Burkhard FC, Bosch JLHR, Cruz F et al. Urinary incontinence. EAU Guidelines. https://uroweb.org/guideline/urinary-incontinence/

  4. Gulur DM, Drake MJ (2010) Management of overactive bladder. Nat Rev Urol 7:572–582

    Article  CAS  Google Scholar 

  5. Smith AL, Wein AJ (2010) Recent advances in management of bladder overactivity. F1000 Med Rep 2:9

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(Suppl):33–46

    Article  CAS  Google Scholar 

  7. Chapple CR, Cardozo L, Nitti VW (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 33(1):17–30. https://doi.org/10.1002/nau.22505[Epub 2013 Oct 11]

    Article  CAS  PubMed  Google Scholar 

  8. Wagg A, Franks B, Ramos B, Berner T (2015) Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J 9:343–350

    Article  Google Scholar 

  9. Nitti VM, Rovner ES, Franks B et al (2016) Persitence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits 8:e25

    Google Scholar 

  10. Acquadro C (2006) Kopp Z Translating overactive bladder questionnaires in 14 languages. Urology. 67(3):536–540

    Article  Google Scholar 

  11. Fabbrini G, Abbruzzese G (2013) Adherence to anti-Parkinson drug therapy in the “REASON” sample of Italian patients with Parkinson’s disease: the linguistic validation of the Italian version of the “Morisky Medical Adherence scale-8 items”. Neurol Sci 34:2015–2022

    Article  CAS  Google Scholar 

  12. Srikrishna S, Robinson D, Cardozo L (2010) Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct 21:523–528

    Article  Google Scholar 

  13. Yeowell G, Smith P et al (2018) Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 8(11):e021889

    Article  Google Scholar 

  14. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47

    Article  Google Scholar 

  15. Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774

    Article  CAS  Google Scholar 

  16. Veenboer PW, Bosch JL (2014) Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 191:1003–1008

    Article  CAS  Google Scholar 

  17. Martan A, Masata J, Krhut J, Zachoval R, Hanus T, Svabik K (2017) Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study. Eur J Obstet Gynecol Reprod Biol 210:247–250

    Article  CAS  Google Scholar 

  18. Wagg A, Compion G et al (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110(11):1767–1774

    Article  CAS  Google Scholar 

  19. Chapple CR, Jameel N et al (2017) Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK. Clin Pract Eur Urol 72(3):389–399

    Article  CAS  Google Scholar 

  20. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K (2018) Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: Prospective, randomized trial. Low Urin. Tract Symptoms. 10(2):148–152

    Article  CAS  Google Scholar 

  21. Sussman D, Yehoshua A, Kowalski J et al (2017) Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract 71:e12824

    Article  Google Scholar 

  22. Hill MN, Miller NH, DeGeest S (2010) ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich) 12:757–764

    Article  Google Scholar 

  23. Duckett J, Balachandran A (2016) Tolerability and persistence in a large, prospective case series of women prescribed mirabegron. Int Urogynecol J 27:1163–1167

    Article  Google Scholar 

  24. Pindoria N, Malde S, Nowers J, Taylor C, Kelleher C, Sahai A (2017) Persistence with mirabegron therapy for overactive bladder: a real life experience. Neurourol Urodyn 36:404–408

    Article  CAS  Google Scholar 

  25. Wada N, Watanabe M, Banjo H (2018) Long-term persistence with mirabegron in a real-world clinical setting. Int J Urol 25(5):501–506

    Article  CAS  Google Scholar 

  26. Hakimi Z (2018) Kelleher C Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. J Mark Access Health Policy 6(1):1438721

    Article  Google Scholar 

  27. Herschorn S, Nazir J (2017) Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Can Urol Assoc J. 11(3–4):123–130

    Article  Google Scholar 

  28. Nazir J, Hakimi A (2018) Z retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. BMC Urol 18(1):76

    Article  Google Scholar 

  29. Serati M, Maggiore LR et al (2017) Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder? Int Urogynecol J 28(7):1033–1039

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Andrologycal and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Piazzale di Joanuccio 1, 05100, Terni, Italy

    Ester Illiano & Elisabetta Costantini

  2. Urology Clinic, TorVergata University, Rome, Italy

    Enrico Finazzi Agrò

  3. Urogynecology Unic, San Carlo Di Nancy Hospital, Rome, Italy

    Franca Natale

  4. Monaldi Hospital, Naples, Italy

    Raffaele Balsamo

Authors
  1. Ester Illiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrico Finazzi Agrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franca Natale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaele Balsamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elisabetta Costantini
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EI: manuscript writing and editing; EFA: data analysis and manuscript editing; FN: data management; RB: data collection; EC: project development.

Corresponding author

Correspondence to Ester Illiano.

Ethics declarations

Conflict of interest

The author(s) declare that they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Illiano, E., Finazzi Agrò, E., Natale, F. et al. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder. Int Urol Nephrol 52, 1035–1042 (2020). https://doi.org/10.1007/s11255-020-02412-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02412-2

Keywords

Search

Navigation